Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies to treat cancer. The company specializes in gene editing technologies to create allogeneic chimeric antigen receptor (CAR) T cells, which are designed to target and destroy cancer cells. Operating in the biopharmaceutical and biotechnology sectors, Cellectis primarily serves healthcare providers and patients in need of advanced cancer treatments. The company's business model revolves around research and development, clinical trials, and partnerships with other pharmaceutical companies, such as Sanofi. Revenue is generated through licensing agreements, milestone payments, and potential future sales of approved therapies. Cellectis aims to revolutionize cancer treatment by providing off-the-shelf CAR T cell therapies that are more accessible and cost-effective compared to traditional autologous CAR T cell therapies.

Keywords: CAR T cells, gene editing, immunotherapy, cancer treatment, biopharmaceutical, biotechnology, clinical trials, allogeneic, partnerships, healthcare.